Literature DB >> 2877883

Pharmacokinetics of single and multiple doses of flusoxolol (Ro 31-1411) in healthy subjects.

H C Gillies, H J Rogers, R J Francis, D B Galloway, J E Humphreys.   

Abstract

Flusoxolol (Ro 31-1411) is the pharmacologically active optical isomer of Ro 31-1118, a potent cardioselective beta-adrenoceptor antagonist with partial agonist activity. It was given to 6 healthy volunteers in a single dose, 40 mg, and then in multiple doses, 40 mg daily for 8 days. Plasma concentration data were best described by a linear two-compartment pharmacokinetic model with first order absorption, and the results confirmed linear kinetics. Pharmacokinetic data for flusoxolol were comparable to those for the racemate Ro 31-1118.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877883     DOI: 10.1007/bf00870998

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.

Authors:  P C O'Connor; J M Arnold; A N Brown; R J Francis; M B Finch; D B Galloway; D W Harron; D G McDevitt; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

2.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation.

Authors:  R J Francis
Journal:  Comput Programs Biomed       Date:  1984 Feb-Apr

4.  Ro 31-1118, a new cardioselective beta-adrenoceptor antagonist. Pharmacokinetics and effects on heart rate and blood pressure in mild hypertensives.

Authors:  M Jamieson; J C Petrie; J Webster; A Miller; R I Harris; R J Francis
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.